NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
19
03
2022
received:
29
12
2021
accepted:
30
04
2022
pubmed:
7
5
2022
medline:
16
11
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
The effects of sex and menopausal status on the association between NAFLD and incident type 2 diabetes (T2D) remain unclear. We investigated the effect modification by sex and menopause in the association between NAFLD and T2D; also, the added predictive ability of NAFLD for the risk of T2D was assessed. This cohort study comprised 245,054 adults without diabetes (109,810 premenopausal women; 4958 postmenopausal women; 130,286 men). Cox proportional hazard models were used to estimate hazard ratios (HRs; 95% confidence intervals [CIs]) for incident T2D according to NAFLD status. The incremental predictive role of NAFLD for incident T2D was assessed using the area under the receiver operating characteristic curve, net reclassification improvement, and integrated discrimination improvement. A total of 8381 participants developed T2D (crude incidence rate/10 NAFLD, including more severe NAFLD, is a stronger risk factor for incident T2D in premenopausal women than in postmenopausal women or men; protection against T2D is lost in premenopausal women with NAFLD.
Sections du résumé
BACKGROUND AND AIMS
The effects of sex and menopausal status on the association between NAFLD and incident type 2 diabetes (T2D) remain unclear. We investigated the effect modification by sex and menopause in the association between NAFLD and T2D; also, the added predictive ability of NAFLD for the risk of T2D was assessed.
APPROACH AND RESULTS
This cohort study comprised 245,054 adults without diabetes (109,810 premenopausal women; 4958 postmenopausal women; 130,286 men). Cox proportional hazard models were used to estimate hazard ratios (HRs; 95% confidence intervals [CIs]) for incident T2D according to NAFLD status. The incremental predictive role of NAFLD for incident T2D was assessed using the area under the receiver operating characteristic curve, net reclassification improvement, and integrated discrimination improvement. A total of 8381 participants developed T2D (crude incidence rate/10
CONCLUSIONS
NAFLD, including more severe NAFLD, is a stronger risk factor for incident T2D in premenopausal women than in postmenopausal women or men; protection against T2D is lost in premenopausal women with NAFLD.
Identifiants
pubmed: 35514152
doi: 10.1002/hep.32560
pii: 01515467-202212000-00018
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1755-1765Informations de copyright
© 2022 American Association for the Study of Liver Diseases.
Références
Targher G, Tilg H, Byrne CD. Non‐alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6:578–88.
Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non‐alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta‐analysis of 501 022 adult individuals. Gut. 2021;70:962–9.
Balakrishnan M, Patel P, Dunn‐Valadez S, Dao C, Khan V, Ali H, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta‐analysis. Clin Gastroenterol Hepatol. 2021;19:61–71.e15.
Mauvais‐Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565–82.
Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med. 2020;9:1278.
Lefebvre P, Staels B. Hepatic sexual dimorphism ‐ implications for non‐alcoholic fatty liver disease. Nat Rev Endocrinol. 2021;17(11):662–70.
Goossens GH, Jocken JWE, Blaak EE. Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver. Nat Rev Endocrinol. 2021;17:47–66.
Tramunt B, Smati S, Grandgeorge N, Lenfant F, Arnal J‐F, Montagner A, et al. Sex differences in metabolic regulation and diabetes susceptibility. Diabetologia. 2020;63:453–61.
Wegermann K, Garrett ME, Zheng J, Coviello A, Moylan CA, Abdelmalek MF, et al. Sex and menopause modify the effect of single nucleotide polymorphism genotypes on fibrosis in NAFLD. Hepatol Commun. 2021;5:598–607.
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–69.
Yang JD, Abdelmalek MF, Guy CD, Gill RM, Lavine JE, Yates K, et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2017;15:127–31.e122.
Yang JD, Abdelmalek MF, Pang H, Guy CD, Smith AD, Diehl AM, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology. 2014;59:1406–14.
Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann AO, Unalp–Arida A, et al. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:786–94.
Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, et al. Alcoholic and non‐alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68:1667–75.
Phipps AI, Ichikawa L, Bowles EJA, Carney PA, Kerlikowske K, Miglioretti DL, et al. Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas. 2010;67:60–6.
World Health Organization, Regional Office for the Western Pacific . The Asia‐Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia; 2000.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–23.
McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non‐invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non‐alcoholic fatty liver disease. Gut. 2010;59:1265–9.
Ampuero J, Pais R, Aller R, Gallego‐Durán R, Crespo J, García‐Monzón C, et al. Development and validation of hepamet fibrosis scoring system–a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol. 2020;18:216–25.e5.
Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30:1105–17.
Bang H, Edwards AM, Bomback AS, Ballantyne CM, Brillon D, Callahan MA, et al. Development and validation of a patient self‐assessment score for diabetes risk. Ann Intern Med. 2009;151:775–83.
Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, et al. The Leicester Risk Assessment score for detecting undiagnosed type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010;27:887–95.
Lonardo A, Carani C, Carulli N, Loria P. 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196–207.
Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47:181–90.
Janssen I, Powell LH, Crawford S, Lasley B, Sutton‐Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. Arch Intern Med. 2008;168:1568–75.
Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32:949–58.
Ni L, Yu D, Wu T, Jin F. Gender‐specific association between non‐alcoholic fatty liver disease and type 2 diabetes mellitus among a middle‐aged and elderly Chinese population: an observational study. Medicine (Baltimore). 2021;100:e24743.
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus ‐ mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18:599–612.
Meex RCR, Watt MJ. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13:509–20.
Stefan N, Haring HU. Circulating fetuin‐A and free fatty acids interact to predict insulin resistance in humans. Nat Med. 2013;19:394–5.
Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73:263–76.
Nemoto Y, Toda K, Ono M, Fujikawa‐Adachi K, Saibara T, Onishi S, et al. Altered expression of fatty acid‐metabolizing enzymes in aromatase‐deficient mice. J Clin Invest. 2000;105:1819–25.
Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond). 2010;34:949–59.
Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non‐alcoholic fatty liver disease: focus on high‐risk groups. Dig Liver Dis. 2015;47:997–1006.
Allen AM, Therneau TM, Mara KC, Larson JJ, Watt KD, Hayes SN, et al. Women with nonalcoholic fatty liver disease lose protection against cardiovascular disease: a longitudinal cohort study. Am J Gastroenterol. 2019;114:1764–71.
Khalid YS, Dasu NR, Suga H, Dasu KN, Reja D, Shah A, et al. Increased cardiovascular events and mortality in females with NAFLD: a meta‐analysis. Am J Cardiovasc Dis. 2020;10:258–71.
Kengne AP, Beulens JWJ, Peelen LM, Moons KGM, van der Schouw YT, Schulze MB, et al. Non‐invasive risk scores for prediction of type 2 diabetes (EPIC‐InterAct): a validation of existing models. Lancet Diabetes Endocrinol. 2014;2:19–29.
Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, Kishore P, et al. Increased intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab. 2007;293:E1663–E1669.
Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–16.
Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with A1C. Diabetes Care. 2011;34(Suppl 2):S184–90.